These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35791871)

  • 1. First Responders' Views of Naloxone: Does Stigma Matter?
    Kruis NE; McLean K; Perry P; Nackley MK
    Subst Use Misuse; 2022; 57(10):1534-1544. PubMed ID: 35791871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring first responders' perceptions of medication for addiction treatment: Does stigma influence attitudes?
    Kruis NE; McLean K; Perry P
    J Subst Abuse Treat; 2021 Dec; 131():108485. PubMed ID: 34098289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'It's the same thing as giving them CPR training': rural first responders' perspectives on naloxone.
    Filteau MR; Green B; Kim F; McBride KA
    Harm Reduct J; 2022 Oct; 19(1):111. PubMed ID: 36192736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of provider attitudes toward #naloxone on Twitter.
    Haug NA; Bielenberg J; Linder SH; Lembke A
    Subst Abus; 2016; 37(1):35-41. PubMed ID: 26860229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
    Adeosun SO
    J Pharm Pract; 2023 Aug; 36(4):941-952. PubMed ID: 35505618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of first responders' intention to refer to post-overdose services following SHIELD training.
    Siddiqui ST; La Manna A; Connors E; Smith R; Vance K; Budesa Z; Goulka J; Beletsky L; Wood CA; Marotta P; Winograd RP
    Harm Reduct J; 2024 Feb; 21(1):39. PubMed ID: 38351046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-level determinants of stakeholder perceptions of community stigma toward people with opioid use disorders, harm reduction services and treatment in the HEALing Communities Study.
    Davis A; Stringer KL; Drainoni ML; Oser CB; Knudsen HK; Aldrich A; Surratt HL; Walker DM; Gilbert L; Downey DL; Gardner SD; Tan S; Lines LM; Vandergrift N; Mack N; Holloway J; Lunze K; McAlearney AS; Huerta TR; Goddard-Eckrich DA; El-Bassel N
    Int J Drug Policy; 2023 Dec; 122():104241. PubMed ID: 37890391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder.
    Jones JD; Campbell AN; Brandt L; Metz VE; Martinez S; Wall M; Corbeil T; Andrews H; Castillo F; Neale J; Strang J; Ross S; Comer SD
    Drug Alcohol Depend; 2022 Aug; 237():109505. PubMed ID: 35709575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incoming medical students' knowledge of and attitudes toward people with substance use disorders: Implications for curricular training.
    Moses TE; Chammaa M; Ramos R; Waineo E; Greenwald MK
    Subst Abus; 2021; 42(4):692-698. PubMed ID: 33166242
    [No Abstract]   [Full Text] [Related]  

  • 10. Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA.
    Bessen S; Metcalf SA; Saunders EC; Moore SK; Meier A; McLeman B; Walsh O; Marsch LA
    Int J Drug Policy; 2019 Dec; 74():144-151. PubMed ID: 31590090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Take-Home Naloxone Kits: Attitudes and Likelihood-Of-Use Outcomes from a European Survey of Potential Overdose Witnesses.
    McDonald R; Breidahl S; Abel-Ollo K; Akhtar S; Clausen T; Day E; Kelleher M; McAuley A; Petersen H; Sefranek M; Thiesen H; Strang J
    Eur Addict Res; 2022; 28(3):220-225. PubMed ID: 35114666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with gaps in naloxone knowledge: evidence from a 2022 great plains survey.
    Cooper-Ohm S; Habecker P; Humeniuk R; Bevins RA
    Harm Reduct J; 2024 Feb; 21(1):37. PubMed ID: 38336722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.
    Spector AL; Galletly CL; Christenson EA; Montaque HDG; Dickson-Gomez J
    BMC Public Health; 2022 Jul; 22(1):1387. PubMed ID: 35854278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Impact of a Tribal Naloxone Program Through Pre and Post Surveys from First Responders.
    McGee S; Greutman M; Cua G; Plested B
    Am Indian Alsk Native Ment Health Res; 2022; 29(3):122-135. PubMed ID: 36178750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emotional reactions of trained overdose responders who use opioids following intervention in an overdose event.
    Brandt L; Campbell ANC; Jones JD; Martinez S; Neale J; Parkin S; Brown C; Strang J; Comer SD
    Subst Abus; 2022; 43(1):581-591. PubMed ID: 34520679
    [No Abstract]   [Full Text] [Related]  

  • 16. Harm Reduction in the Field: First Responders' Perceptions of Opioid Overdose Interventions.
    Elswick Fockele C; Frohe T; McBride O; Perlmutter DL; Goh B; Williams G; Wettemann C; Holland N; Finegood B; Oliphant-Wells T; Williams EC; van Draanen J
    West J Emerg Med; 2024 Jul; 25(4):490-499. PubMed ID: 39028235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 18. "They're not doing enough.": women's experiences with opioids and naloxone in Toronto.
    Macleod ER; Tajbakhsh I; Hamilton-Wright S; Laliberte N; Wiese JL; Matheson FI
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):26. PubMed ID: 33743756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concerns that an opioid antidote could "make things worse": Profiles of risk compensation beliefs using the Naloxone-Related Risk Compensation Beliefs (NaRRC-B) scale.
    Winograd RP; Werner KB; Green L; Phillips S; Armbruster J; Paul R
    Subst Abus; 2020; 41(2):245-251. PubMed ID: 31170030
    [No Abstract]   [Full Text] [Related]  

  • 20. Opioid Use Disorder Stigma and Support for Harm Reduction in Rural Counties.
    Whipple CR; Kaynak Ö; Kruis NE; Saylor E; Bonnevie E; Kensinger WS
    Subst Use Misuse; 2023; 58(14):1818-1828. PubMed ID: 37622487
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.